

Donald G Grosset

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3716044/donald-g-grosset-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

129
papers

4,906
citations

37
h-index

67
g-index

147
ext. papers

5,788
ext. citations

5.7
avg, IF

5.34
L-index

#	Paper	IF	Citations
129	Accurate differentiation of parkinsonism and essential tremor using visual assessment of [¹ I]-FP-CIT SPECT imaging: The [¹ I]-FP-CIT study group. <i>Movement Disorders</i> , 2000 , 15, 503-510	7	551
128	Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake. <i>Movement Disorders</i> , 2000 , 15, 692-8	7	283
127	Role of dopamine transporter imaging in routine clinical practice. <i>Movement Disorders</i> , 2003 , 18, 1415-23		183
126	Role of DAT-SPECT in the diagnostic work up of parkinsonism. <i>Movement Disorders</i> , 2007 , 22, 1229-38	7	180
125	Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [¹²³ I]FP-CIT SPECT. <i>Movement Disorders</i> , 2009 , 24, 500-8	7	157
124	Suboptimal medication adherence in Parkinson's disease. <i>Movement Disorders</i> , 2005 , 20, 1502-7	7	155
123	Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study. <i>Movement Disorders</i> , 2006 , 21, 343-53	7	154
122	Parkinson's disease age at onset genome-wide association study: Defining heritability, genetic loci, and Lysynuclein mechanisms. <i>Movement Disorders</i> , 2019 , 34, 866-875	7	136
121	Adherence to antiparkinson medication in a multicenter European study. <i>Movement Disorders</i> , 2009 , 24, 826-32	7	131
120	Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table. <i>Movement Disorders</i> , 2004 , 19, 1370-4	7	105
119	Neuroprotection for acute stroke: making clinical trials work. <i>Stroke</i> , 1999 , 30, 180-2	6.7	100
118	Prospective study of presynaptic dopaminergic imaging in patients with mild parkinsonism and tremor disorders: part 1. Baseline and 3-month observations. <i>Movement Disorders</i> , 2003 , 18, 977-84	7	93
117	Vascular disease and vascular risk factors in relation to motor features and cognition in early Parkinson's disease. <i>Movement Disorders</i> , 2016 , 31, 1518-1526	7	90
116	Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging. <i>Nuclear Medicine Communications</i> , 2006 , 27, 933-7	1.6	88
115	Patient-perceived involvement and satisfaction in Parkinson's disease: effect on therapy decisions and quality of life. <i>Movement Disorders</i> , 2005 , 20, 616-9	7	83
114	Accuracy of clinical diagnosis in tremulous parkinsonian patients: a blinded video study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010 , 81, 1223-8	5.5	79
113	The parkinsonism-hyperpyrexia syndrome. <i>Neurocritical Care</i> , 2009 , 10, 136-40	3.3	77

112	Differentiating vascular parkinsonism from idiopathic Parkinson's disease: a systematic review. <i>Movement Disorders</i> , 2010 , 25, 149-56	7	73
111	A systematic review of the epidemiology of epilepsy in Arab countries. <i>Epilepsia</i> , 2009 , 50, 2301-4	6.4	72
110	Medicine-taking behavior: implications of suboptimal compliance in Parkinson's disease. <i>Movement Disorders</i> , 2005 , 20, 1397-404	7	70
109	Genetic modifiers of risk and age at onset in GBA associated Parkinson's disease and Lewy body dementia. <i>Brain</i> , 2020 , 143, 234-248	11.2	69
108	Stroke in Arab countries: a systematic literature review. <i>Journal of the Neurological Sciences</i> , 2009 , 284, 18-23	3.2	68
107	Perindopril reduces blood pressure but not cerebral blood flow in patients with recent cerebral ischemic stroke. <i>Stroke</i> , 1997 , 28, 580-3	6.7	68
106	Developing and validating Parkinson's disease subtypes and their motor and cognitive progression. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018 , 89, 1279-1287	5.5	66
105	A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease. <i>Movement Disorders</i> , 2016 , 31, 1356-65	7	61
104	Medication adherence in patients with Parkinson's disease. <i>CNS Drugs</i> , 2015 , 29, 47-53	6.7	58
103	Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009 , 15, 728-41	3.6	57
102	Features of -associated Parkinson's disease at presentation in the UK study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018 , 89, 702-709	5.5	55
101	Frequency and clinical patterns of multiple sclerosis in Arab countries: a systematic review. <i>Journal of the Neurological Sciences</i> , 2009 , 278, 1-4	3.2	55
100	Angiographic and Doppler diagnosis of cerebral artery vasospasm following subarachnoid haemorrhage. <i>British Journal of Neurosurgery</i> , 1993 , 7, 291-8	1	53
99	Intercenter agreement in reading Doppler embolic signals. A multicenter international study. <i>Stroke</i> , 1997 , 28, 1307-10	6.7	52
98	A detailed clinical study of pain in 1957 participants with early/moderate Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018 , 56, 27-32	3.6	49
97	Effect of educational intervention on medication timing in Parkinson's disease: a randomized controlled trial. <i>BMC Neurology</i> , 2007 , 7, 20	3.1	45
96	Detection of intracranial emboli in patients with carotid disease. <i>European Journal of Vascular Surgery</i> , 1994 , 8, 309-14		44
95	Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Syndrome. <i>JAMA Neurology</i> , 2020 , 77, 377-387	17.2	44

94	[123I]FP-CIT (DaTscan) SPECT brain imaging in patients with suspected parkinsonian syndromes. <i>Journal of Neuroimaging</i> , 2012 , 22, 225-30	2.8	40
93	Pathological gambling in Parkinson's disease--a review of the literature. <i>Movement Disorders</i> , 2011 , 26, 1976-84	7	38
92	Neuropathology of dementia in patients with Parkinson's disease: a systematic review of autopsy studies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019 , 90, 1234-1243	5.5	37
91	Therapy adherence issues in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2010 , 289, 115-8	3.2	36
90	Accuracy of Parkinson's disease diagnosis in 610 general practice patients in the West of Scotland. <i>Movement Disorders</i> , 2009 , 24, 2379-85	7	36
89	Role of dopamine transporter imaging in the diagnosis of atypical tremor disorders. <i>Movement Disorders</i> , 2003 , 18 Suppl 7, S22-7	7	36
88	Equating scores of the University of Pennsylvania Smell Identification Test and Sniffin' Sticks test in patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016 , 33, 96-101	3.6	36
87	Genetic analysis of Mendelian mutations in a large UK population-based Parkinson's disease study. <i>Brain</i> , 2019 , 142, 2828-2844	11.2	35
86	Vascular parkinsonism: a clinical review. <i>European Neurology</i> , 2009 , 61, 11-5	2.1	34
85	Tracking Parkinson's: Study Design and Baseline Patient Data. <i>Journal of Parkinson's Disease</i> , 2015 , 5, 947-59	5.3	31
84	Diagnosing restless legs syndrome (RLS) in primary care. <i>Current Medical Research and Opinion</i> , 2004 , 20, 1785-95	2.5	29
83	Inhaled apomorphine in patients with 'on-off' fluctuations: a randomized, double-blind, placebo-controlled, clinic and home based, parallel-group study. <i>Journal of Parkinson's Disease</i> , 2013 , 3, 31-7	5.3	28
82	Epidemiology of headache in Arab countries. <i>Journal of Headache and Pain</i> , 2010 , 11, 1-3	8.8	28
81	Successful antiparkinsonian medication withdrawal in patients with Parkinsonism and normal FP-CIT SPECT. <i>Movement Disorders</i> , 2006 , 21, 2247-50	7	27
80	Tolerability of the low-affinity, use-dependent NMDA antagonist AR-R15896AR in stroke patients: a dose-ranging study. <i>Stroke</i> , 2001 , 32, 466-72	6.7	27
79	Genome-Wide Association Studies of Cognitive and Motor Progression in Parkinson's Disease. <i>Movement Disorders</i> , 2021 , 36, 424-433	7	27
78	Geographical difference in Parkinson's disease prevalence within West Scotland. <i>Movement Disorders</i> , 2009 , 24, 401-6	7	26
77	Parkinson's disease in Arabs: a systematic review. <i>Movement Disorders</i> , 2008 , 23, 1205-10	7	26

76	Identification of echocardiographic "smoke" in a bench model with transcranial Doppler ultrasound. <i>Stroke</i> , 2000 , 31, 907-14	6.7	26
75	Is ioflupane I123 injection diagnostically effective in patients with movement disorders and dementia? Pooled analysis of four clinical trials. <i>BMJ Open</i> , 2014 , 4, e005122	3	24
74	Prodromal Markers in Parkinson's Disease: Limitations in Longitudinal Studies and Lessons Learned. <i>Frontiers in Aging Neuroscience</i> , 2016 , 8, 147	5.3	23
73	Precompetitive Data Sharing as a Catalyst to Address Unmet Needs in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2015 , 5, 581-94	5.3	22
72	Effects of prolonged infusions of the NMDA antagonist aptiganel hydrochloride (CNS 1102) in normal volunteers. <i>Clinical Neuropharmacology</i> , 1997 , 20, 311-21	1.4	21
71	Prescription of drugs with potential adverse effects on cardiac conduction in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2013 , 19, 586-9	3.6	20
70	Proposed dose equivalence for rapid switching between dopamine agonists in Parkinson's disease. <i>Clinical Therapeutics</i> , 2006 , 28, 1063-4; author reply 1064	3.5	19
69	Updated guidelines for the management of Parkinson's disease. <i>British Journal of Hospital Medicine</i> , 2001 , 62, 456-70		19
68	Systemic and cerebral hemodynamic responses to the noncompetitive N-methyl-D-aspartate (NMDA) antagonist CNS 1102. <i>Journal of Cardiovascular Pharmacology</i> , 1995 , 25, 705-9	3.1	19
67	Statins are underused in recent-onset Parkinson's disease with increased vascular risk: findings from the UK Tracking Parkinson's and Oxford Parkinson's Disease Centre (OPDC) discovery cohorts. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 1183-1190	5.5	19
66	Autonomic Dysfunction in Early Parkinson's Disease: Results from the United Kingdom Tracking Parkinson's Study. <i>Movement Disorders Clinical Practice</i> , 2017 , 4, 509-516	2.2	18
65	Dopamine agonists and therapy compliance. <i>Neurological Sciences</i> , 2008 , 29 Suppl 5, S375-6	3.5	18
64	Variation in Recent Onset Parkinson's Disease: Implications for Prodromal Detection. <i>Journal of Parkinson's Disease</i> , 2016 , 6, 289-300	5.3	18
63	Safety analysis of 10 clinical trials and for 13 years after first approval of ioflupane 123I injection (DaTscan). <i>Journal of Nuclear Medicine</i> , 2014 , 55, 1281-7	8.9	17
62	The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2019 , 9, 553-563	5.3	16
61	Methods in Neuroepidemiology Characterization of European Longitudinal Cohort Studies in Parkinson's Disease--Report of the JPND Working Group BioLoC-PD. <i>Neuroepidemiology</i> , 2015 , 45, 282-97	5.4	16
60	A randomized trial of specialized versus standard neck physiotherapy in cervical dystonia. <i>Parkinsonism and Related Disorders</i> , 2016 , 23, 72-9	3.6	15
59	Noninvasive options for 'wearing-off' in Parkinson's disease: a clinical consensus from a panel of UK Parkinson's disease specialists. <i>Neurodegenerative Disease Management</i> , 2018 , 8, 349-360	2.8	15

58	Individual-reader diagnostic performance and between-reader agreement in assessment of subjects with Parkinsonian syndrome or dementia using 123I-ioflupane injection (DaTscan) imaging. <i>Journal of Nuclear Medicine</i> , 2014 , 55, 1288-96	8.9	14
57	Switch from abobotulinumtoxinA (Dysport®) to incobotulinumtoxinA (Xeomin®) botulinum toxin formulation: a review of 257 cases. <i>Journal of Rehabilitation Medicine</i> , 2015 , 47, 183-6	3.4	14
56	Clinical follow up of pathological gambling in Parkinson's disease in the West Scotland study. <i>Movement Disorders</i> , 2009 , 24, 2430-1	7	14
55	Dopamine agonist switching in Parkinson's disease. <i>British Journal of Hospital Medicine</i> , 2004 , 65, 215-9		13
54	On the origin of cerebrovascular microemboli associated with prosthetic heart valves. <i>Neurological Research</i> , 1995 , 17, 349-352	2.7	13
53	Inhaled levodopa in Parkinson's disease patients with OFF periods: A randomized 12-month pulmonary safety study. <i>Parkinsonism and Related Disorders</i> , 2020 , 71, 4-10	3.6	13
52	Trial of subtherapeutic pergolide in de novo Parkinson's disease. <i>Movement Disorders</i> , 2005 , 20, 363-6	7	11
51	Clinical pharmacology of CNS 1102 in volunteers. <i>Annals of the New York Academy of Sciences</i> , 1995 , 765, 279-89; discussion 298	6.5	11
50	L-dopa responsiveness in early Parkinson's disease is associated with the rate of motor progression. <i>Parkinsonism and Related Disorders</i> , 2019 , 65, 55-61	3.6	10
49	Aiming for Study Comparability in Parkinson's Disease: Proposal for a Modular Set of Biomarker Assessments to be Used in Longitudinal Studies. <i>Frontiers in Aging Neuroscience</i> , 2016 , 8, 121	5.3	10
48	Utility of the new Movement Disorder Society clinical diagnostic criteria for Parkinson's disease applied retrospectively in a large cohort study of recent onset cases. <i>Parkinsonism and Related Disorders</i> , 2017 , 40, 40-46	3.6	9
47	Analysis of DNM3 and VAMP4 as genetic modifiers of LRRK2 Parkinson's disease. <i>Neurobiology of Aging</i> , 2021 , 97, 148.e17-148.e24	5.6	9
46	Cognitive impairment in Parkinson's disease is multifactorial: A neuropsychological study. <i>Acta Neurologica Scandinavica</i> , 2020 , 141, 500-508	3.8	8
45	The genetic and clinico-pathological profile of early-onset progressive supranuclear palsy. <i>Movement Disorders</i> , 2019 , 34, 1307-1314	7	8
44	Pergolide in Parkinson's disease: time for a change?. <i>Lancet, The</i> , 2004 , 363, 1907-8	4.0	7
43	Dopamine agonists vs levodopa in impulse control disorders. <i>Archives of Neurology</i> , 2011 , 68, 544-5; author reply 545-6		6
42	Anticoagulant monitoring with transcranial Doppler. <i>Lancet, The</i> , 1995 , 345, 57-8	4.0	6
41	Parkinson disease age of onset GWAS: defining heritability, genetic loci and a-synuclein mechanisms		6

40	Investigation of Autosomal Genetic Sex Differences in Parkinson's Disease. <i>Annals of Neurology</i> , 2021 , 90, 35-42	9.4	6
39	Genome-Wide Association Study of Pain in Parkinson's Disease Implicates TRPM8 as a Risk Factor. <i>Movement Disorders</i> , 2020 , 35, 705-707	7	5
38	Testing Shortened Versions of Smell Tests to Screen for Hyposmia in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2020 , 7, 394-398	2.2	5
37	Statin usage, vascular diagnosis and vascular risk factors in Parkinson's disease. <i>Scottish Medical Journal</i> , 2017 , 62, 104-109	1.8	5
36	Timing the initiation of treatment in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008 , 79, 615	5.5	5
35	Olfactory Testing in Parkinson Disease and REM Behavior Disorder: A Machine Learning Approach. <i>Neurology</i> , 2021 , 96, e2016-e2027	6.5	5
34	Should stroke medicine be a separate subspecialty? 1997 , 315, 1167-1168		4
33	Factor structure of the Montreal Cognitive Assessment in Parkinson disease. <i>International Journal of Geriatric Psychiatry</i> , 2020 , 35, 188-194	3.9	4
32	Genome-Wide Association Study Meta-Analysis for Parkinson Disease Motor Subtypes. <i>Neurology: Genetics</i> , 2021 , 7, e557	3.8	4
31	Hedonistic homeostatic dysregulation in Parkinson's disease and excess dopamine replacement therapy. <i>Movement Disorders</i> , 2005 , 20, 1230-1	7	3
30	Characterization of ultrasound-detected cerebral microemboli in patients undergoing cardiac catheterization using an in vitro middle cerebral artery model. <i>Catheterization and Cardiovascular Interventions</i> , 2001 , 53, 323-30	2.7	3
29	Clinical pharmacology of CNS 1102 in man. <i>Annals of the New York Academy of Sciences</i> , 1995 , 765, 336-76.5		3
28	Turbulence and circulating cerebral emboli detectable at Doppler ultrasonography: a differentiation study in a stenotic middle cerebral artery model. <i>American Journal of Neuroradiology</i> , 2002 , 23, 1229-36	4.4	3
27	Genetic Stratification of Age-Dependent Parkinson's Disease Risk by Polygenic Hazard Score. <i>Movement Disorders</i> , 2021 ,	7	3
26	Natural history of lung function over one year in patients with Parkinson's disease. <i>Respiratory Medicine</i> , 2021 , 182, 106396	4.6	3
25	Unilateral arm tremor as the sole feature of ischemic stroke: a 5-year follow up. <i>Movement Disorders</i> , 2000 , 15, 346-7	7	2
24	Transesophageal echocardiography microbubbles with prosthetic valves. <i>American Heart Journal</i> , 1995 , 130, 1312	4.9	2
23	The association between pain and impulse control behaviours in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2020 , 78, 53-55	3.6	2

22	Comparison between four published definitions of hyposmia in Parkinson's disease. <i>Brain and Behavior</i> , 2021 , 11, e2258	3.4	2
21	Parkinson's disease and related disorders--XVIII WFN World Congress. <i>IDrugs: the Investigational Drugs Journal</i> , 2010 , 13, 82-4		2
20	Nonmotor symptoms in patients without evidence of dopaminergic deficit. <i>Movement Disorders</i> , 2016 , 31, 429-30	7	1
19	Rare case of atypical parkinsonism: why family history is important. <i>Scottish Medical Journal</i> , 2017 , 62, 159-162	1.8	1
18	Reply: The meaning of negative DAT and F-Dopa PET scans in a patient with clinical Parkinson's disease. <i>Movement Disorders</i> , 2005 , 20, 118-118	7	1
17	Maximising information on smell, quantitative motor impairment and probable REM-sleep behaviour disorder in the prediction of Parkinson's disease		1
16	Universal latent axes capturing Parkinson's patient deep phenotypic variation reveals patients with a high genetic risk for Alzheimer's disease are more likely to develop a more aggressive form of Parkinson's		1
15	Spheramine Titan/Schering. <i>Current Opinion in Investigational Drugs</i> , 2005 , 6, 722-8		1
14	Optimising classification of Parkinson's disease based on motor, olfactory, neuropsychiatric and sleep features. <i>Npj Parkinson's Disease</i> , 2021 , 7, 87	9.7	0
13	Orofacial pain in 1916 patients with early or moderate Parkinson disease. <i>Pain Reports</i> , 2021 , 6, e923	3.5	0
12	Overview of Dopamine Transporter Imaging in Parkinson's Disease, Dementia with Lewy Bodies and Other Dementias. <i>Current Geriatrics Reports</i> , 2015 , 4, 124-130	1.3	
11	NEUROMELANIN-SENSITIVE RESONANCE IMAGING AS A PARKINSON'S DISEASE BIOMARKER. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, e1.10-e1	5.5	
10	EFFECTS OF VASCULAR COMORBIDITY IN PARKINSON'S DISEASE. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, e1.13-e1	5.5	
9	Enhancing dopamine treatments: worth the effort?. <i>Neurodegenerative Disease Management</i> , 2012 , 2, 365-373	2.8	
8	TRACKING PARKINSON'S (THE PROBAND STUDY) INTERIM REPORT FROM THE FIRST 1000 CASES. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013 , 84, e2.70-e2	5.5	
7	Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of neurodegenerative disease management.. <i>Neurodegenerative Disease Management</i> , 2013 , 3, 303-305	2.8	
6	Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of neurodegenerative disease management. <i>Neurodegenerative Disease Management</i> , 2011 , 1, 97-99	2.8	
5	Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of neurodegenerative disease management. <i>Neurodegenerative Disease Management</i> , 2011 , 1, 357-359	2.8	

4	Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of neurodegenerative disease management. <i>Neurodegenerative Disease Management</i> , 2011 , 1, 187-189	2.8
3	Pill counts, self reports, and electronic monitoring -- which is most informative in the study of therapy adherence in Parkinson's disease?. <i>Movement Disorders</i> , 2007 , 22, 2294	7
2	Dopamine transporter imaging. <i>Movement Disorders</i> , 2003 , 18 Suppl 7, S1-2	7
1	228 Testing shortened versions of smell tests to screen for hyposmia in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022 , 93, A79.2-A79	5.5